JMP Securities Trims Taysha Gene Therapies (NASDAQ:TSHA) Target Price to $6.00

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) had its target price cut by equities researchers at JMP Securities from $20.00 to $6.00 in a report released on Thursday, The Fly reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ price target suggests a potential upside of 209.28% from the stock’s current price.

TSHA has been the topic of several other reports. Needham & Company LLC cut their target price on Taysha Gene Therapies from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, November 8th. The Goldman Sachs Group downgraded Taysha Gene Therapies from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 9th. Canaccord Genuity Group assumed coverage on Taysha Gene Therapies in a research report on Tuesday, November 8th. They set a “buy” rating and a $16.00 price target on the stock. BTIG Research cut their price target on Taysha Gene Therapies from $25.00 to $15.00 in a research report on Thursday, November 10th. Finally, Guggenheim cut their price target on Taysha Gene Therapies from $22.00 to $19.00 in a research report on Tuesday, November 8th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.08.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.30 and a quick ratio of 1.30. The stock’s fifty day moving average price is $2.18 and its 200 day moving average price is $2.76. Taysha Gene Therapies has a 1 year low of $1.35 and a 1 year high of $8.93. The company has a market cap of $121.14 million, a price-to-earnings ratio of -0.47 and a beta of 1.29.

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) last released its earnings results on Tuesday, November 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.25. As a group, equities research analysts forecast that Taysha Gene Therapies will post -3.09 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, Director Paul B. Manning purchased 1,500,000 shares of the company’s stock in a transaction on Monday, October 31st. The stock was acquired at an average price of $2.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the director now directly owns 1,642,202 shares in the company, valued at approximately $3,284,404. The purchase was disclosed in a filing with the SEC, which is available through this link. 42.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of TSHA. Kovitz Investment Group Partners LLC acquired a new stake in Taysha Gene Therapies in the fourth quarter valued at $34,000. AQR Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth about $38,000. Sargent Investment Group LLC increased its position in Taysha Gene Therapies by 41.9% in the 3rd quarter. Sargent Investment Group LLC now owns 25,242 shares of the company’s stock valued at $47,000 after acquiring an additional 7,454 shares during the period. Occudo Quantitative Strategies LP increased its position in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company’s stock valued at $115,000 after acquiring an additional 4,702 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its position in Taysha Gene Therapies by 33.3% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 56,100 shares of the company’s stock valued at $209,000 after acquiring an additional 14,000 shares during the period. Institutional investors and hedge funds own 45.12% of the company’s stock.

Taysha Gene Therapies Company Profile

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories

The Fly logo

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.